7-溴-2-氯喹啉 | 99455-15-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-溴-2-氯喹啉
• 英文名称: 7-bromo-2-chloroquinoline
• CAS: 99455-15-9
• 化学式: C₉H₅BrClN
• 分子量: 242.502
• InChiKey: MOEWRAKNXMILKB-UHFFFAOYSA-N

物化性质

• 熔点：
  120-121 °C
• 沸点：
  325.7±22.0 °C(Predicted)
• 密度：
  1.673±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933499090
• WGK Germany：
  3
• 危险标志：
  GHS05,GHS06
• 危险性描述：
  H301,H318
• 危险性防范说明：
  P280,P301 + P310,P305 + P351 + P338
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-2-chloro-quinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H318: Causes serious eye damage
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-2-chloro-quinoline
CAS number: 99455-15-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H5BrClN
Molecular weight: 242.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (7-Bromo-2-chloro-quinoline)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-2-氯喹啉 在 乙酰胺 、 potassium carbonate 作用下， 反应 18.0h， 以75%的产率得到2-氨基-7-溴喹啉
  参考文献：
  名称：

  孔中的腈：神经元一氧化氮合酶中一个小的辅助口袋的发现，导致有效和选择性的2-氨基喹啉抑制剂的发展。

  摘要：

  抑制神经元一氧化氮合酶（nNOS）是治疗神经退行性疾病的一种有前途的策略，但是不良的药代动力学通常会阻碍nNOS抑制剂的发展。我们先前开发了一类可透过膜的2-氨基喹啉抑制剂，后来重新排列了支架以减少脱靶结合。但是，与人eNOS相比，所得化合物的通透性降低，人nNOS活性低，选择性低。在这项研究中，合成了5-取代的苯基醚连接的氨基喹啉及其衍生物，并针对纯化的NOS同工型进行了分析。5-氰基化合物是特别有效的和选择性的大鼠和人类nNOS抑制剂。活性和选择性是由氰基与nNOS中新的辅助口袋的结合所介导的。通过喹啉的甲基化和引入简单的手性部分可增强效价，从而产生疏水和辅助口袋效应的组合，从而产生高（约500倍）n / e选择性。重要的是，Caco-2分析还显示了比先前化合物更高的膜通透性。

  DOI：

  10.1021/acs.jmedchem.7b00259
• 作为产物：
  描述：

  N-(3-bromophenyl)cinnamamide 在 三氯化铝 、 三氯氧磷 作用下， 以 氯苯 为溶剂， 生成 7-溴-2-氯喹啉
  参考文献：
  名称：

  新型噻吩并吡啶磺酰胺吡咯烷酮作为Xa因子抑制剂的合成，SAR和体内活性。

  摘要：

  发现噻吩并吡啶磺酰胺吡咯烷酮是凝血级联酶因子Xa的有效和选择性抑制剂。SAR研究导致选择了几种化合物进行进一步的体内研究。这些新颖的芳基结合口袋部分代表了一系列fXa抑制剂的结构修饰。几种化合物被证明是有效的静脉抗血栓药。

  DOI：

  10.1016/s0960-894x(99)00466-7

文献信息

• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150368278A1

  公开（公告）日：2015-12-24

  The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。
• [EN] MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES<br/>[FR] INHIBITEURS MACROCYCLIQUES DES VIRUS FLAVIVIRIDAE
  申请人：GILEAD SCIENCES INC

  公开号：WO2013185103A1

  公开（公告）日：2013-12-12

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

  提供的是Formula I的化合物及其药用可接受的盐和酯。所提供的化合物、组合物和方法对于治疗病毒感染，特别是丙型肝炎感染，是有用的。
• MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
  申请人：Gilead Sciences, Inc.

  公开号：US20170190737A1

  公开（公告）日：2017-07-06

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

  提供的是公式I的化合物： 及其药用可接受的盐和酯。这些化合物、组合物和方法对于治疗病毒感染特别是有用的，尤其是丙型肝炎感染。
• Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle
  作者：Richard L. Mackman、Victoria A. Steadman、David K. Dean、Petr Jansa、Karine G. Poullennec、Todd Appleby、Carol Austin、Caroline A. Blakemore、Ruby Cai、Carina Cannizzaro、Gregory Chin、Jean-Yves C. Chiva、Neil A. Dunbar、Hans Fliri、Adrian J. Highton、Hon Hui、Mingzhe Ji、Haolun Jin、Kapil Karki、Andrew J. Keats、Linos Lazarides、Yu-Jen Lee、Albert Liclican、Michael Mish、Bernard Murray、Simon B. Pettit、Peter Pyun、Michael Sangi、Rex Santos、Jonathan Sanvoisin、Uli Schmitz、Adam Schrier、Dustin Siegel、David Sperandio、George Stepan、Yang Tian、Gregory M. Watt、Hai Yang、Brian E. Schultz

  DOI：10.1021/acs.jmedchem.8b00802

  日期：2018.11.8

  discover through total synthesis an orally bioavailable, non-immunosuppressive cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus (HCV) activity that could serve as part of an all oral antiviral combination therapy. An initial lead 2 derived from the sanglifehrin A macrocycle was optimized using structure based design to produce a potent and orally bioavailable inhibitor 3. The macrocycle ring

  亲环蛋白是一个肽基脯氨酰异构酶家族，涉及多种疾病，包括丙型肝炎。我们的目标是通过全合成发现具有有效抗丙型肝炎病毒的口服生物利用型，非免疫抑制性亲环蛋白（Cyp）抑制剂（ HCV）活性可以作为所有口服抗病毒药物联合治疗的一部分。使用基于结构的设计优化了衍生自sanglifehrin A大环的初始铅2，以产生有效的口服生物利用抑制剂3。大环环的尺寸减少了一个原子，并且内部的氢键推动了磁导率和类药物性质的改善。3证明有效的Cyp抑制作用（K d= 5 nM），有效的抗HCV 2a活性（EC 50 = 98 nM）和大鼠（100％）和狗（55％）的高口服生物利用度。合成可达性和性能的3支持它的潜力作为抗HCV剂和用于询问在多种疾病CYP抑制的作用。
• Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
  申请人：Prelude Therapeutics, Incorporated

  公开号：US20190048014A1

  公开（公告）日：2019-02-14

  The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

  该披露涉及到I式化合物，还描述了包括I式化合物的药物组合物，以及它们的使用和制备方法。